osi-027 and Carcinoma--Basal-Cell

osi-027 has been researched along with Carcinoma--Basal-Cell* in 1 studies

Other Studies

1 other study(ies) available for osi-027 and Carcinoma--Basal-Cell

ArticleYear
MTOR promotes basal cell carcinoma growth through atypical PKC.
    Experimental dermatology, 2021, Volume: 30, Issue:3

    Advanced basal cell carcinomas (BCCs) are driven by the Hedgehog (HH) pathway and often possess inherent resistance to SMO inhibitors. Identifying and targeting pathways that bypass SMO could provide alternative treatments for patients with advanced or metastatic BCC. Here, we use a combination of RNA-sequencing analysis of advanced human BCC tumor-normal pairs and immunostaining of human and mouse BCC samples to identify an MTOR expression signature in BCC. Pharmacological inhibition of MTOR activity in BCC cells significantly reduces cell proliferation without affecting HH signalling. Similarly, treatment of the Ptch1 

    Topics: Animals; Antineoplastic Agents; Carcinoma, Basal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Hedgehog Proteins; Humans; Imidazoles; Immunohistochemistry; Mice; Patched-1 Receptor; Protein Kinase C; Sequence Analysis, RNA; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases; Triazines; Zinc Finger Protein GLI1

2021